StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research note issued to investors on Thursday morning. The firm issued a buy rating on the biotechnology company’s stock.
Other equities research analysts have also issued reports about the company. Guggenheim reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. HC Wainwright reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Mizuho reduced their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $2.79.
Check Out Our Latest Analysis on ADAP
Adaptimmune Therapeutics Price Performance
Hedge Funds Weigh In On Adaptimmune Therapeutics
Large investors have recently made changes to their positions in the business. Invesco Ltd. lifted its holdings in Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 28,526 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 58,787 shares in the last quarter. Two Sigma Investments LP lifted its holdings in Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 19,146 shares in the last quarter. Virtu Financial LLC lifted its holdings in Adaptimmune Therapeutics by 21.5% in the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 21,688 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Adaptimmune Therapeutics in the 3rd quarter worth approximately $95,000. 31.37% of the stock is currently owned by hedge funds and other institutional investors.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Read More
- Five stocks we like better than Adaptimmune Therapeutics
- Investing In Preferred Stock vs. Common Stock
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Are Penny Stocks a Good Fit for Your Portfolio?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Invest in Blue Chip Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.